Peptide Protocol
Peptide Protocol
 App Store

AOD-9604: the complete guide

AOD-9604 is a synthetic fragment of the C-terminal region of human growth hormone (amino acids 176–191). It was developed as a potential obesity treatment to retain HGH's lipolytic activity without its growth-promoting effects.

Written by Peptide Protocol Editorial Medically reviewed per our review process Last reviewed
ClassModified growth hormone fragment (residues 176–191)
Half-lifeApproximately 30 minutes (plasma)
Typical dose250–500 mcg per injection, once daily (typically fasted)
CategoryMetabolic / fat loss
Research useFat loss research, body-composition protocols
FDA statusNot FDA approved. Holds GRAS (Generally Recognized as Safe) self-affirmation in the US as a supplement ingredient. Clinical trials did not show significant weight loss vs placebo.

How AOD-9604 works

AOD-9604 is believed to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat formation) through a mechanism independent of the GH receptor, though the exact pathway is still debated.

Typical AOD-9604 dosage

Commonly reported research ranges: 250–500 mcg per injection, once daily (typically fasted).

Dose should always be individualized. Factors that influence it include bodyweight, research goal, tolerance, and specific compound batch. The information below is educational, not a prescription.

How to reconstitute AOD-9604

A widely used reconstitution for a 5 mg vial is 2 ml of bacteriostatic water. With a typical 300 mcg dose this works out to the unit count shown in the calculator below.

Open the AOD-9604 reconstitution calculator →

Pre-filled with the common 5 mg + 2 ml ratio. Adjust for your own vial.

Half-life and administration frequency

Approximately 30 minutes (plasma).

This half-life informs how often AOD-9604 is typically dosed. Shorter half-lives usually mean more frequent dosing to maintain plasma levels; longer half-lives allow daily, weekly, or less-frequent administration depending on the compound.

Reported side effects

This list reflects effects reported in available literature or user logs. It is not exhaustive. Adverse reactions should be discussed with a qualified clinician.

Common AOD-9604 stacks

Storage and handling

Lyophilized refrigerated. Reconstituted: refrigerated, use within 28 days.

FDA and regulatory status

Not FDA approved. Holds GRAS (Generally Recognized as Safe) self-affirmation in the US as a supplement ingredient. Clinical trials did not show significant weight loss vs placebo.

AOD-9604 clinical trials and evidence

For clinical-trial and primary-literature context, start with the sources below. We prioritize official drug labels, ClinicalTrials.gov records, and PubMed-indexed literature when available.

Track your AOD-9604 protocol on iPhone

Peptide Protocol logs every dose, calculates reconstitution for you, and keeps your full protocol on one calm screen.

See the app →

Frequently asked questions

What is AOD-9604?

AOD-9604 is a synthetic fragment of the C-terminal region of human growth hormone (amino acids 176–191). It was developed as a potential obesity treatment to retain HGH's lipolytic activity without its growth-promoting effects.

How does AOD-9604 work?

AOD-9604 is believed to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat formation) through a mechanism independent of the GH receptor, though the exact pathway is still debated.

What is a typical AOD-9604 dose?

Commonly reported ranges are 250–500 mcg per injection, once daily (typically fasted). This is research information, not a recommendation — dosing should be individualized under clinical guidance.

What is the half-life of AOD-9604?

Approximately 30 minutes (plasma). This influences how often it is administered.

How do you reconstitute AOD-9604?

A common approach is to add 2 ml of bacteriostatic water to a 5 mg vial. Use the reconstitution calculator for exact unit counts.

What are the side effects of AOD-9604?

Generally well-tolerated in trials; Mild injection-site reactions; Rare headache or nausea.

Is AOD-9604 FDA approved?

Not FDA approved. Holds GRAS (Generally Recognized as Safe) self-affirmation in the US as a supplement ingredient. Clinical trials did not show significant weight loss vs placebo.

Are there clinical trials for AOD-9604?

Registered or published clinical-trial sources for AOD-9604 are listed in the references section below. Evidence depth varies widely by compound, so check the cited trial registries and primary literature before relying on any claim.

References

  1. AOD-9604 / HGH fragment 176-191 literature — PubMed. Primary studies on the C-terminal HGH fragment and lipolytic activity in preclinical models
  2. Ng & Bornstein — AOD9604 clinical evaluation — PubMed. Human obesity trial data — failed to meet primary weight-loss endpoint
  3. AOD-9604 clinical trial records — ClinicalTrials.gov. Registered human studies

Sources listed above were used to verify the claims on this page. See our editorial policy for how we source information.

Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.